Immunotherapy for advanced nasopharyngeal cancer after chemo
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 18 to 65 years old
- Newly diagnosed with a type of nasopharyngeal cancer called non-keratinizing carcinoma
- Cancer is stage II or III (spread to nearby areas but not distant organs)
- You have already finished 3 cycles of GP chemotherapy plus a PD-1 inhibitor without your cancer getting worse
- You are generally healthy enough for treatment (able to do daily activities, blood counts and organ function are adequate)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests if adding an immunotherapy drug (toripalimab) to standard chemotherapy works better than chemotherapy alone for children and teens with advanced nasopharyngeal cancer (a type of nose cancer). The goal is to improve outcomes for newly diagnosed patients.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.